A number of other brokerages also recently commented on BTG. Peel Hunt reaffirmed a hold rating and issued a GBX 680 ($8.94) price target on shares of BTG plc in a report on Tuesday, October 31st. Deutsche Bank AG reaffirmed a buy rating and issued a GBX 775 ($10.19) price target on shares of BTG plc in a report on Tuesday, November 7th. Numis Securities Ltd reaffirmed a buy rating and issued a GBX 900 ($11.84) price target on shares of BTG plc in a report on Wednesday, October 18th. Finally, Stifel Nicolaus reaffirmed a buy rating and issued a GBX 800 ($10.52) price target on shares of BTG plc in a report on Wednesday, August 30th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of GBX 779.13 ($10.25).
Shares of BTG plc (BTG) traded up GBX 7.49 ($0.10) during trading hours on Wednesday, hitting GBX 710.99 ($9.35). 907,654 shares of the company were exchanged, compared to its average volume of 722,306. BTG plc has a 1 year low of GBX 528.36 ($6.95) and a 1 year high of GBX 779 ($10.25).
BTG plc (LON:BTG) last announced its quarterly earnings results on Tuesday, November 14th. The company reported GBX 21 ($0.28) EPS for the quarter, meeting the Zacks’ consensus estimate of GBX 21 ($0.28). BTG plc had a net margin of 7.26% and a return on equity of 4.33%. The firm had revenue of £341.30 million during the quarter.
COPYRIGHT VIOLATION NOTICE: “BTG plc (BTG) Receives “Neutral” Rating from J P Morgan Chase & Co” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://ledgergazette.com/2017/11/16/btg-plc-btg-receives-neutral-rating-from-j-p-morgan-chase-co.html.
BTG plc Company Profile
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with MarketBeat.com's FREE daily email newsletter.